
Teva Pharmaceuticals (TEVA), the generic drug maker based in Israel, posted good Q1 results today with revenue beating analysts' forecasts. Despite earnings falling short of projections, Teva reaffirmed its forecast for significant free cash flow in 2024.
As a result, TEVA stock is 13% higher to $15.81 per share in morning trading. That has also led to unusual call options activity today based on a Barchart report.